Clinical Outcomes for Severe COVID-19 Patients with Comorbid Type 2 DM through Dexamethasone Therapy at RSUP Dr. Sardjito Yogyakarta

https://doi.org/10.22146/jmpf.96954

Novia Ariani Dewi(1*), Tri Murti Andayani(2), Ika Trisnawati(3)

(1) Pharmacy Study Program, Faculty of Health, Universitas Jenderal Achmad Yani, Yogyakarta
(2) Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(3) Department of Internal Medicine, Division of Pulmonology, Faculty of Public Health Medicine and Nursing, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author

Abstract


Background: Dexamethasone is a recommended therapy for severe COVID-19 patients who require hospital treatment. However, its use can affect blood glucose levels in patients, especially patients with diabetes mellitus comorbidity.

Objectives: This study aims to determine the clinical outcomes for type 2 diabetes mellitus (DM) patients with Severe COVID-19 comorbidity through dexamethasone as COVID-19 therapy.

Methods: This study employed the retrospective cohort an analytical observational research approach. Involving 60 patients as subjects, patients over the age of 18 received dexamethasone at RSUP Dr. Sardjito Yogyakarta between June 2021 and March 2022 and whose RT-PCR results showed severe COVID-19 with comorbidity of type 2 DM were included in the study. The blood glucose profiles derived from the patient's medical record data were the clinical outcome that already checked. The paired t-test was performed to analyze how dexamethasone affected the clinical results of the blood glucose profile.

Results: The findings of the study were identified after using dexamethasone for four days, which showed that 78.30% of patients had an increased in blood glucose. Pre and post treatment of dexamethasone for four days had a significant impact on the patient’s blood glucose levels in this study, with an average change in blood glucose levels is 78.32 ± 116.77 (p<0.05).

Conclusion: Dexamethasone therapy demonstrates a significant effect on blood glucose levels, resulting in a statistically difference between pre and post values for four days in patients with severe COVID-19 with type 2 DM comorbidity. Consequently, special monitoring needs to be carried out in severe COVID-19 patients with type 2 DM who receive dexamethasone to avoid worsening of the patient’s clinical condition.


Keywords


COVID-19; Dexamethasone; Diabetes mellitus; Clinical Outcomes

Full Text:

PDF


References

  1. Azar WS, Njeim R, Fares AH, et al. COVID-19 and diabetes mellitus: how one pandemic worsens the other. Rev Endocr Metab Disord. 2020;21(4):451-463. doi:10.1007/s11154-020-09573-6
  2. Velavan TP, Meyer CG. The COVID-19 epidemic. Tropical Medicine & International Health. 2020;25(3):278-280. doi:10.1111/TMI.13383
  3. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. Journal of Community Empowerment for Health. 2020;3(2):77-84. doi:10.22146/JCOEMPH.57325
  4. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. Journal of Clinical Virology. 2020;127:104354. doi:10.1016/J.JCV.2020.104354
  5. Lee MH, Wong C, Ng CH, Yuen DCW, Lim AYL, Khoo CM. Effects of hyperglycaemia on complications of COVID-19: A meta-analysis of observational studies. Diabetes Obes Metab. 2021;23(1):287-289. doi:10.1111/DOM.14184
  6. Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract. 2020;164:108214. doi:10.1016/J.DIABRES.2020.108214
  7. Padda I, Parmar MS. Corticosteroids. Encyclopedia of Toxicology, Fourth Edition: Volume 1-9. 2023;3:V3-251-V3-258. doi:10.1016/B978-0-12-824315-2.00367-5
  8. NIH. COVID-19 Treatment Guidelines. 2022. Accessed June 6, 2024. https://www.covid19treatmentguidelines.nih.gov/
  9. Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96-102. doi:10.1002/DMRR.2486
  10. Nassar M, Daoud A, Nso N, et al. Diabetes Mellitus and COVID-19: Review Article. Diabetes Metab Syndr. 2021;15(6):102268. doi:10.1016/J.DSX.2021.102268
  11. Suh S, Park MK. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. Endocrinology and Metabolism. 2017;32(2):180-189. doi:10.3803/ENM.2017.32.2.180
  12. Douin DJ, Krause M, Williams C, et al. Corticosteroid Administration and Impaired Glycemic Control in Mechanically Ventilated COVID-19 Patients. Semin Cardiothorac Vasc Anesth. 2022;26(1):32-40. doi:10.1177/10892532211043313
  13. Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1):337. doi:10.1186/s12879-021-06045-3
  14. Sterne JAC, Murthy S, Diaz J V., et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. JAMA. 2020;324(13):1330. doi:10.1001/jama.2020.17023
  15. Wang Y, Jiang W, He Q, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. Published online March 12, 2020. doi:10.1101/2020.03.06.20032342
  16. Lemeshow S, Hosmer Jr DW, Klar J, Lwanga SK. Adequacy of Sample Size in Health Studies. World Health Organization. Published online 1990.
  17. Harbuwono DS, Handayani DOTL, Wahyuningsih ES, et al. Impact of diabetes mellitus on COVID-19 clinical symptoms and mortality: Jakarta’s COVID-19 epidemiological registry. Prim Care Diabetes. 2022;16(1):65-68. doi:10.1016/j.pcd.2021.11.002
  18. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. Journal of Community Empowerment for Health. 2020;3(2):77. doi:10.22146/jcoemph.57325
  19. IDF. IDF Diabetes Atlas Seventh Edition. In: International Diabetes Federation; 2015.
  20. Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom. 2022;91(1):8-35. doi:10.1159/000521288
  21. Alessi J, de Oliveira GB, Schaan BD, Telo GH. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetol Metab Syndr. 2020;12(1):80. doi:10.1186/s13098-020-00583-7
  22. Rhou YJJ, Hor A, Wang M, et al. Dexamethasone-induced hyperglycaemia in COVID-19: Glycaemic profile in patients without diabetes and factors associated with hyperglycaemia. Diabetes Res Clin Pract. 2022;194:110151. doi:10.1016/j.diabres.2022.110151
  23. Zhang F, Karam JG. Glycemic Profile of Intravenous Dexamethasone-Induced Hyperglycemia Using Continuous Glucose Monitoring. American Journal of Case Reports. 2021;22. doi:10.12659/AJCR.930733
  24. Brooks D, Schulman-Rosenbaum R, Griff M, Lester J, Low Wang CC. Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review. Endocrine Practice. 2022;28(11):1166-1177. doi:10.1016/J.EPRAC.2022.07.014
  25. Mathew P, Thoppil D. Hypoglycemia. StatPearls. Published online December 26, 2022. Accessed June 7, 2024. https://www.ncbi.nlm.nih.gov/books/NBK534841/
  26. Burhan E, Dwi Susanto A, Isbaniah F, et al. PEDOMAN TATALAKSANA COVID-19 Edisi 4 TIM EDITOR Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi Dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). 4th ed. Perhimpunan Dokter Paru Indonesia (PDPI); 2022.
  27. Abani O, Abbas A, Abbas F, et al. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2023;401(10387):1499-1507. doi:10.1016/S0140-6736(23)00510-X
  28. Douin DJ, Krause M, Williams C, et al. Corticosteroid Administration and Impaired Glycemic Control in Mechanically Ventilated COVID-19 Patients. Semin Cardiothorac Vasc Anesth. 2022;26(1):32-40. doi:10.1177/10892532211043313/ASSET/IMAGES/LARGE/10.1177_10892532211043313-FIG2.JPEG



DOI: https://doi.org/10.22146/jmpf.96954

Article Metrics

Abstract views : 279 | views : 35

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats